Problems with Salvage Trials

• Diverse patient population (treatment history, resistance)

• New agent trials designed for licensing: difficult to show efficacy in salvage situation

  • DCPG 2000-2001 trials offered:
  • 8 for “naïves”
  • 2 “experienced” but restrictive (e.g: first PI failure, NNRTI naïve)
  • 2 salvage: tenofovir expanded access, PEG-interferon

Previous slide

Next slide

Back to first slide

View graphic version